HLNCF 4.07 Stock Price Haleon plc
Range: | 3.9-5.36 | Vol Avg: | 51075 | Last Div: | 0.08 | Changes: | -0.1 |
Beta: | 0.24 | Cap: | 40.56B | Currency: | USD | Exchange: | PNK |
Sector: | Healthcare | IPO: | Thu Jul 28 2022 | Empoloyees: | 25408 |
CUSIP: | | CIK: | 0001900304 | ISIN: | GB00BMX86B70 | Country: | GB |
CEO: | Mr. Brian James McNamara | Website: | https://www.haleon.com |
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.